about
The Relation Between Migraine, Typical Migraine Aura and “Visual Snow”Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis.The role of the cerebellum in multiple sclerosis.Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST).Migraine pathogenesis and state of pharmacological treatment optionsReliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).Positron emission tomography ligand activation studies in the sports sciences: measuring neurochemistry in vivo.Kinetic modelling of [11C]flumazenil using data-driven methods.What has functional neuroimaging done for primary headache ... and for the clinical neurologist?[Studies on cerebral processing of pain using functional imaging : Somatosensory, emotional, cognitive, autonomic and motor aspects].Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration.White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal studyTension type headache in adolescence and childhood: where are we now?Hypothalamic deep brain stimulation in positron emission tomography.The origin of nausea in migraine-a PET study.The runner's high: opioidergic mechanisms in the human brain.Label-fusion-segmentation and deformation-based shape analysis of deep gray matter in multiple sclerosis: the impact of thalamic subnuclei on disability.Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis.Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMSMigraine changes the brain: neuroimaging makes its mark.What to learn from in vivo opioidergic brain imaging?Genetic associations with brain cortical thickness in multiple sclerosisNew onset migraine with aura after treatment initiation with ivabradine.Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis.Current practice and future directions in the prevention and acute management of migraine.Interferon beta-associated recurrence of painful trigeminal neuropathy attributed to a multiple sclerosis plaqueTrigeminal neuropathic pain in a patient with progressive facial hemiatrophy (parry-romberg syndrome).The complexities of pain after stroke--a review with a focus on central post-stroke pain.The typical duration of migraine aura: a systematic review.Is the migrainous brain normal outside of acute attacks? Lessons learned from psychophysical, neurochemical and functional neuroimaging studies.Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA.The premonitory phase of migraine--what can we learn from it?Daclizumab for the treatment of multiple sclerosis.Reduced volume of the nucleus accumbens in heroin addiction.Teriflunomide for oral therapy in multiple sclerosis.Repeated pain induces adaptations of intrinsic brain activity to reflect past and predict future pain.Assessing the risk of central post-stroke pain of thalamic origin by lesion mapping.
P50
Q29012691-6303A34A-10F0-4878-A918-90325121C0B9Q30699612-7223C20A-2050-4B7D-A056-A46CB0C6FD3DQ30884001-32EEEA12-B74D-424D-986F-6C727EF6FD37Q30885558-3AAF87A8-DF69-46B6-8072-199F2CE535E0Q30886663-CF4723CD-7475-44CE-A261-640D8F18D8F4Q31094277-4F3FC025-14DB-4346-8388-B6BE2213D2F7Q31167584-295125B0-D6E6-4D72-AEE2-A81F4A8EDAC7Q33388271-3BC940E0-421F-43B6-9D18-07BDA6F9F4E9Q33540506-89853209-35BE-428A-9244-034B31565C1EQ33550874-E31DEC14-FA23-41CA-B96D-108E9A655462Q33937672-C8721E3C-AE85-4FF4-9C40-8E1D0861DFA3Q34184999-5E85B1EB-1BAD-468E-891F-6A161F252388Q34242892-6BD26A8A-D128-470E-98D9-C6AE6D68F3F5Q34651955-14E3F4B2-0758-4188-BBC9-C1C2028A749AQ34703211-7FD2234E-3A4F-4E2E-ABD5-1707D877D6E6Q34754624-BDE1AAD6-AF1C-4455-9880-84B6ADC69CAFQ35089562-2C52E4F5-5787-443D-8451-01844CCE6EB7Q35116652-5BA8F84F-8CBE-4EBC-8356-23A9755295DAQ35639941-D08C522E-1FC4-42CD-A4C5-95A0E159A198Q35846504-E14E2E8E-857D-400F-A1D3-DDFB742EB30DQ35850708-A88D244F-20C7-4078-93BB-BBF8DA1856E6Q36049968-A8A7CD70-7E9C-490F-BDB4-0DA1D19ED1DBQ36057731-FA22E6EA-A8EF-4663-9D7F-48EE2AE327E6Q36872589-01D06211-F77A-413C-996F-9A89309002B1Q36926428-47C7997F-F87A-4CEE-9A6D-A5FAD636675BQ37505897-E2D8A3C0-AD3A-422A-8125-056F7FAB40F7Q37695402-46870E07-BD9B-4C22-B4A2-1BA55CAE262DQ37733975-3EB5CDB8-921D-4C4C-BBA6-E77C753ABD98Q37900070-9157EAF5-FC19-4C01-9BAC-A179E05E0CFEQ38087835-A2451491-7A7B-4088-88A1-2C674F8C5BC6Q38087899-B275162A-783C-4AD6-A7C0-BB03037A78C6Q38140024-DD0E5D11-0108-415C-9E5D-41C04E22070BQ38357590-CD203FBC-5B2B-4429-8575-7D846C7BF530Q38371842-B4584E25-BB6C-45A5-912A-DF9A356EA768Q38446240-49F82B14-CA86-47D5-B9CD-C5D0D49FF06BQ38604207-FA7095AD-943D-4185-9534-9D614403E89FQ39085350-C485E383-ECA6-4E85-99D8-990C140A0274Q39504360-5D40092E-5E78-4625-A85D-72FD32A232D9Q39757801-E1BAA6A5-B053-4437-BD8D-6C6C88F4F973Q40043065-C61E73F5-029E-484D-B592-69484CD497E9
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Till Sprenger
@ast
Till Sprenger
@en
Till Sprenger
@es
Till Sprenger
@nl
Till Sprenger
@sl
type
label
Till Sprenger
@ast
Till Sprenger
@en
Till Sprenger
@es
Till Sprenger
@nl
Till Sprenger
@sl
prefLabel
Till Sprenger
@ast
Till Sprenger
@en
Till Sprenger
@es
Till Sprenger
@nl
Till Sprenger
@sl
P106
P1153
23019897600
P21
P31
P496
0000-0002-5390-819X